```
     FILE 'REGISTRY' ENTERED AT 16:12:04 ON 22 OCT 2010
L1                STRUCTURE UPLOADED
L2             0 S L1
L3             3 S L1 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 16:12:49 ON 22 OCT 2010
L4             3 S L3

     FILE 'REGISTRY' ENTERED AT 16:32:25 ON 22 OCT 2010
L5                STRUCTURE UPLOADED
L6             0 S L5
L7             5 S L5 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 16:33:34 ON 22 OCT 2010
L8             4 S L7
```

```
=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.22       0.22

FILE 'REGISTRY' ENTERED AT 16:12:04 ON 22 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 OCT 2010  HIGHEST RN 1246809-78-8
DICTIONARY FILE UPDATES:  21 OCT 2010  HIGHEST RN 1246809-78-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10546132left.str
```





chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24 25 26 27 28
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 48
ring nodes :
1 2 3 4 5 6
chain bonds :
1-11 2-10 3-7 5-9 6-25 7-8 8-24 9-48 10-23 11-12 12-13 13-14 14-15
14-21
15-16 16-17 17-18 18-19 19-20 25-26 26-27 26-28 28-29 29-30 30-31 31-32
32-33 33-34
34-35 35-36 36-37 37-38 39-40 40-41 42-43 43-44
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6

```
exact/norm bonds :
1-2  1-6  1-11  2-3  2-10  3-4  4-5  5-6  5-9  6-25  9-48  10-23  14-21  25-26
26-27
39-40
exact bonds :
3-7  7-8  8-24  11-12  12-13  13-14  14-15  15-16  16-17  17-18  18-19  19-20  26-28
28-29  29-30  30-31  31-32  32-33  33-34  34-35  35-36  36-37  37-38  40-41  42-43
43-44


G1:H,P

G2:H,[*1],[*2]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS
21:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS  29:CLASS
30:CLASS  31:CLASS
32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS  39:CLASS
40:CLASS  41:CLASS
42:CLASS  43:CLASS  44:CLASS  48:CLASS



L1      STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 16:12:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      442 TO ITERATE

100.0% PROCESSED      442 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         7579 TO    10101
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss full
FULL SEARCH INITIATED 16:12:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     8843 TO ITERATE

100.0% PROCESSED     8843 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

L3            3 SEA SSS FUL L1
```

=> d l3 scan

L3 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) 1-(2,2,2-trichloroethanimidate)
MF C44 H78 Cl3 N2 O10 P

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L3 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-
MF C39 H73 N O7

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 3 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl
    2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-
    1-yl]amino]-, 4-(di-2-propen-1-yl phosphate)
MF C45 H82 N O10 P

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	191.54	191.76

FILE 'HCAPLUS' ENTERED AT 16:12:49 ON 22 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Oct 2010 VOL 153 ISS 18
FILE LAST UPDATED: 21 Oct 2010 (20101021/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 3 L3

=> d l4 1-3 ti abs bib hitstr

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Sodium salt of glucosamine disaccharide compound, method for producing the same, and use of the same
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed a sodium salt represented by the average formula (I; m1, n1, m2 and n2 independently represent 0 or a pos. number not more than 2, while satisfying m1 + n1 =2, m2 + n2 =2, 0 < m1 + m2 < 4 and 0 < n1 + n2 < 4.) and a method for producing such a sodium salt. There is also a decomposition suppressing method which enables to have a sodium salt represented by the average formula I coexistent with a sodium salt represented by the general formula II below. This method enables to improve long-term stability of a sodium salt represented by the general formula II which is effective for the prevention and/or treatment of septicemia caused by gram pos. bacteria, in particular endotoxin shock. Thus, a DEAE column main fraction containing 6.0 g disaccharide free acid (III) (preparation given) and 4.80 weight% Na and 942.8 L MeOH were stirred in a 4 L flask at 25°, treated with 0.2 N NaOH/MeOH solution (15.2 mL), stirred overnight, filtered, and treated dropwise with 270 mL acetone at 25°. The precipitate was removed by filtration and dried in vacuo to give III.3.67 Na. When III.3.67 Na was stored in a screw-cap bottle at 25° for 30 days, impurities A, B, and C were formed at a rate of 0.072, 0.267, and 0.072 %/mo, resp., vs. 0.729. 3.117, and 0.033 %/mo, resp., for III.4.06Na.
AN 2008:636616 HCAPLUS <<LOGINID::20101022>>
DN 149:10241
TI Sodium salt of glucosamine disaccharide compound, method for producing the same, and use of the same
IN Sakurai, Shin; Furukawa, Ken; Matsuo, Kimihiro; Tagami, Kenichi
PA Eisai R & D Management Co., Ltd., Japan
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008062842	A1	20080529	WO 2007-JP72579	20071121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

AU	2007322712	A1	20080529	AU 2007-322712	20071121
CA	2669674	A1	20080529	CA 2007-2669674	20071121
US	20080227991	A1	20080918	US 2007-984770	20071121
KR	2009082506	A	20090730	KR 2009-7012851	20071121
EP	2096116	A1	20090902	EP 2007-832309	20071121

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS

CN	101541820	A	20090923	CN 2007-80043153	20090521
US	20100152429	A1	20100617	US 2009-516082	20091210
PRAI JP	2006-315020	A	20061122		
US	2006-860483P	P	20061122		
WO	2007-JP72579	W	20071121		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 748165-18-6P 748165-20-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of sodium salt of glucosamine disaccharide compound
with storage stability, method for producing it, and its use for prevention and/or treatment of endotoxin shock)

RN 748165-18-6 HCAPLUS

CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-20-0 HCAPLUS

CN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) 1-(2,2,2-trichloroethanimidate) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 748165-17-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sodium salt of glucosamine disaccharide compound with storage
stability, method for producing it, and its use for prevention and/or treatment of endotoxin shock)
RN 748165-17-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Process for production of lipid A analogue
GI



I

AB There is disclosed a process for producing 3-O-decyl-2-deoxy-6-O-[2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecenyl]amino]-4-O-phosphono-β-D-glucopyranosyl]-2-[(1,3-dioxotetradecyl)amino]-α-D-glucopyranose 1-(dihydrogen phosphate) (known as eritoran) tetrasodium salt (I; R = PO3Na2) which is useful as an active ingredient of a pharmaceutical or an intermediate for the synthesis thereof. A process for producing the compound I (R = PO3Na2) comprises the key steps of reacting a compound represented by the formula I [R = P(O)(OCH2CH:CH2)2] with a palladium catalyst in the presence of a nucleophilic agent (deallylation) and treating the product with a sodium source (sodium salt formation). This process is environment-friendly and excellent in safety, operationability, and reproducibility. Thus, a solution of 101.6 g I [R = P(O)(OCH2CH:CH2)2] in 203 mL THF was added to a mixture of Meldrum's acid 70.49, palladium acetate 2.93, and PPh3 51.3 g and the resulting mixture was stirred at 32° for 2 h and at 30° for 4 h, treated with 250 mL MeOH, and concentrated under reduced pressure to give a residue (466.7 g). The residue was dissolved in 4,570 mL MeOH at 40°, treated with 5.55 g trimercaptotriazine, stirred overnight at room temperature, and filtered to remove the precipitated trimercaptotriazine-palladium complex, followed by washing the precipitate with MeOH to give a combined filtrate (4,330 g). The filtrate (3,908.2 mL) was concentrated under reduced pressure to give a residue (440.9 g) which was treated with 450 mL acetone, concentrated under reduced pressure, treated again with 450 mL acetone, and concentrated under reduced pressure. The residue was refrigerated overnight, treated with 1,800 mL acetone, warmed to 40°, stirred for 1.5 h, air-cooled, stirred at ≥30° for 1.5 h, and filtered to give, after washing with acetone and drying at 35-40° under reduced pressure, 74.2% eritoran (free acid form) which was treated with 0.1 N aqueous NaOH solution to give eritoran tetrasodium salt.

AN 2007:257680 HCAPLUS <<LOGINID::20101022>>

DN 146:317153

TI Process for production of lipid A analogue

IN Tagami, Katsuya; Sato, Keizo; Matsuo, Kimihiro; Abe, Taichi; Haga, Toyokazu

PA Eisai R & D Management Co., Ltd., Japan

SO PCT Int. Appl., 69pp.
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007026675	A1	20070308	WO 2006-JP316941	20060829

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU	2006285926	A1	20070308	AU 2006-285926		20060829
CA	2620027	A1	20070308	CA 2006-2620027		20060829
EP	1939209	A1	20080702	EP 2006-796921		20060829

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

KR	2008039374	A	20080507	KR 2008-7000572		20080109
CN	101238140	A	20080806	CN 2006-80027144		20080124
IN	2008CN01457	A	20081128	IN 2008-CN1457		20080325
US	20090149647	A1	20090611	US 2008-64450		20080815
PRAI US	2005-712431P	P	20050831			
JP	2005-253044	A	20050901			
WO	2006-JP316941	W	20060829			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 146:317153

IT 748165-18-6P 748165-20-0P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for production of lipid A analog (eritoran) via palladium-catalyzed deallylation of eritoran diallyl ester and formation of sodium salt)

RN 748165-18-6 HCAPLUS

CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 748165-20-0 HCAPLUS

CN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate)

1-(2,2,2-trichloroethanimidate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 748165-17-5
    RL: RCT (Reactant); RACT (Reactant or reagent)
    (process for production of lipid A analog (eritoran) via palladium-catalyzed deallylation of eritoran diallyl ester and formation of sodium salt)
RN 748165-17-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides methods for preparing lipopolysaccharides (LPS) antagonist lipo-disaccharide B1287 and stereoisomers thereof, which compds. are useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock (no biol. data). Also provided are synthetic intermediates useful for implementing the inventive methods. Thus, lipo-disaccharide B1287 I was prepared for treatment of various forms of septic shock.

AN 2004:718552 HCAPLUS <<LOGINID::20101022>>
DN 141:225771

TI Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock

IN Fan, Rulin
PA Eisai Co, Ltd., Japan

SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074303	A2	20040902	WO 2004-US4921	20040218
	WO 2004074303	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2006518394	T	20060810	JP 2006-503710	20040218
	US 20060160999	A1	20060720	US 2005-546132	20051212
PRAI	US 2003-448839P	P	20030220		
	WO 2004-US4921	W	20040218		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 141:225771; MARPAT 141:225771

IT 748165-17-5P 748165-18-6P 748165-20-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reagents and methods for preparing lipopolysaccharides antagonist b and stereoisomers thereof for treatment of various forms of septic shock)

RN 748165-17-5 HCAPLUS

CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-1-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-18-6 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl
2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-[[(11Z)-1-oxo-11-octadecen-
1-yl]amino]-, 4-(di-2-propen-1-yl phosphate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-20-0 HCAPLUS
CN α-D-Glucopyranose, 2-deoxy-3-O-[(3R)-3-methoxydecyl]-6-O-methyl-2-
[[(11Z)-1-oxo-11-octadecen-1-yl]amino]-, 4-(di-2-propen-1-yl phosphate)
1-(2,2,2-trichloroethanimidate) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:11:50 ON 22 OCT 2010)

FILE 'REGISTRY' ENTERED AT 16:12:04 ON 22 OCT 2010
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 3 S L1 SSS FULL

FILE 'HCAPLUS' ENTERED AT 16:12:49 ON 22 OCT 2010
L4 3 S L3

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.34	212.10
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.55	-2.55

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:13:03 ON 22 OCT 2010

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 16:32:18 ON 22 OCT 2010

FILE 'HCAPLUS' ENTERED AT 16:32:18 ON 22 OCT 2010
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.34	212.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.55	-2.55

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.34	212.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.55	-2.55

FILE 'REGISTRY' ENTERED AT 16:32:25 ON 22 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 21 OCT 2010 HIGHEST RN 1246809-78-8
DICTIONARY FILE UPDATES: 21 OCT 2010 HIGHEST RN 1246809-78-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10546132right.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
28 29 30 31 32 33 34 35 36 37 38 39 46 47 48 49 50 51 52 53 54
55 56 57 58
59 60 61 62 63 64 73 75 76 77 78 79 80 81 82 83 84 85 86 87 94
ring nodes :
1 2 3 4 5 6 40 41 42 43 44 45 65 66 67 68 69 70 71 72 74 91

chain bonds :
1-11 2-10 3-7 5-9 7-8 8-22 9-36 10-21 11-12 12-13 13-14 14-15 15-16
16-17 17-18 18-19 19-20 23-24 23-94 24-25 24-26 26-27 27-28 27-39 28-29
29-30 30-31 31-32
32-33 33-34 34-35 36-37 37-38 40-50 41-49 42-46 44-48 46-47 47-61 48-62
49-60 50-51
51-52 52-53 53-54 54-55 55-56 56-57 57-58 58-59 62-63 63-64 65-75 69-73
73-85 75-76
76-77 77-78 78-79 79-80 80-81 81-82 82-83 83-84 85-86 86-87

```
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  40-41  40-45  41-42  42-43  43-44  44-45  65-66  65-70
66-67  66-74  67-68  67-71  68-69  69-70  71-72  72-91  74-91
exact/norm bonds :
1-2  1-6  1-11  2-3  2-10  3-4  4-5  5-6  5-9  9-36  23-24  23-94  24-25  27-39
40-41  40-45  40-50  41-42  41-49  42-43  43-44  44-45  44-48  48-62  65-66  65-70
65-75  66-67  66-74
67-68  67-71  68-69  69-70  69-73  71-72  72-91  73-85  74-91
exact bonds :
3-7  7-8  8-22  10-21  11-12  12-13  13-14  14-15  15-16  16-17  17-18  18-19  19-20
24-26  26-27  27-28  28-29  29-30  30-31  31-32  32-33  33-34  34-35  36-37  37-38
42-46  46-47
47-61  49-60  50-51  51-52  52-53  53-54  54-55  55-56  56-57  57-58  58-59  62-63
63-64  75-76
76-77  77-78  78-79  79-80  80-81  81-82  82-83  83-84  85-86  86-87


G1:[*1],[*2],[*3]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS
21:CLASS  22:CLASS  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS
29:CLASS  30:CLASS
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS
39:CLASS  40:Atom
41:Atom  42:Atom  43:Atom  44:Atom  45:Atom  46:CLASS  47:CLASS  48:CLASS  49:CLASS
 50:CLASS
51:CLASS  52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS
61:CLASS  62:CLASS  63:CLASS  64:CLASS  65:Atom  66:Atom  67:Atom  68:Atom  69:Atom
 70:Atom  71:Atom
72:Atom  73:CLASS  74:Atom  75:CLASS  76:CLASS  77:CLASS  78:CLASS  79:CLASS
80:CLASS  81:CLASS
82:CLASS  83:CLASS  84:CLASS  85:CLASS  86:CLASS  87:CLASS  91:Atom  94:CLASS



L5      STRUCTURE UPLOADED

=> s l5
SAMPLE SEARCH INITIATED 16:32:51 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      591 TO ITERATE

100.0% PROCESSED      591 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         10362 TO    13278
PROJECTED ANSWERS:                0 TO        0

L6            0 SEA SSS SAM L5

=> s l5 sss full
FULL SEARCH INITIATED 16:33:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    12449 TO ITERATE

100.0% PROCESSED    12449 ITERATIONS                                  5 ANSWERS
```

SEARCH TIME: 00.00.01

L7 5 SEA SSS FUL L5

=> d l7 scan

L7 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN β-D-Glucopyranoside, (1E)-1-propen-1-yl
3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-
MF C39 H75 N O7 Si

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L7 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C36 H65 N O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl
3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]-
MF C39 H75 N O7 Si

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C36 H65 N O7

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 5 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN α-D-Glucopyranoside, (1Z)-1-propen-1-yl
3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]-
MF C33 H61 N O7

Absolute stereochemistry.
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> 0
0 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	192.03	404.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.55

FILE 'HCAPLUS' ENTERED AT 16:33:34 ON 22 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Oct 2010 VOL 153 ISS 18
FILE LAST UPDATED: 21 Oct 2010 (20101021/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7
L8 4 L7

=> d l8 1-4 ti abs bib hitstr

L8 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of glucose lipid A analogs inhibiting macrophage activity
GI



I

AB Title compds. I [Q = -O-, alkylene, -O-alkylene, etc.; W = -O- or -NH-; when W is -NH-, R1 is alkanoyl, alkenoyl, alkynoyl. (wherein alkanoyl, alkenoyl and alkynoyl are optionally substituted with halo, hydroxy, oxo, etc.); each R1 (when W is -O-), R2, R3, and R4 is H, alkyl, alkenyl, etc. (wherein alkyl and alkenyl are optionally substituted with halo, hydroxy, oxo, etc.); R5 = H, halo, hydroxy, etc.] and their pharmacol. acceptable salts were prepared For example, phosphono 3-O-decyl-2-deoxy-6-O-[3-O-[(R)-3-methoxydecyl]-6-O-methyl-2-O-[(Z)-11-octadecenoyl]-4-O-phosphono-β-D-glucopyranosyl]-2-(3-oxotetradecanoylamino)-α-D-glucopyranoside (II) was prepared from 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose in 18 steps. In human TNFα production inhibition assays, the IC50 value of compound II was 0.49 nM. Compds. I are claimed useful for the treatment of inflammation, autoimmune diseases, etc.
AN 2007:167289 HCAPLUS <<LOGINID::20101022>>
DN 146:252059
TI Preparation of glucose lipid A analogs inhibiting macrophage activity
IN Shiozaki, Masao; Shimozato, Ryuichi
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 86pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2007039450	A	20070215	JP 2006-187298	20060707
PRAI	JP 2005-199518	A	20050708		

OS MARPAT 146:252059
IT 859508-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of glucose lipid analogs for treatment of inflammation and

autoimmune diseases)
RN 859508-28-4 HCAPLUS
CN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L8 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Syntheses of glucose-containing E5564 analogs and their LPS-antagonistic activities
AB Lipid A analogs containing a glucose moiety on their non-reducing end were synthesized, and their LPS-antagonistic activities were measured. The inhibitory activities (IC50) on LPS-induced TNFα production of title aminodeoxy disaccharides toward human whole blood cells were 0.46-1.11 nM. Inhibitory doses (ID50) of these compds. on TNFα production induced by co-injection of galactosamine and LPS in C3H/HeN mice were measured. The ID50 values of these compds. were 0.20-1.08 and <0.2 mg/kg. Moreover, C3H/HeN mice preinjected with compds. were protected from lethality induced by co-injection of galactosamine and LPS. Out of eight mice preinjected with 1 mg/kg of title compds. five-eight mice were protected.
AN 2005:1299295 HCAPLUS <<LOGINID::20101022>>
DN 144:171174
TI Syntheses of glucose-containing E5564 analogs and their LPS-antagonistic activities
AU Shiozaki, Masao; Doi, Hiromi; Tanaka, Daisuke; Shimozato, Takaichi; Kurakata, Shin-ichi
CS Chemistry Department, Chemtech Labo, Inc., Hiromachi 1-2-58, Shinagawa-ku, Tokyo, 140-8710, Japan
SO Tetrahedron (2005), Volume Date 2006, 62(1), 205-225
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier B.V.
DT Journal
LA English
OS CASREACT 144:171174
IT 859508-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(syntheses of glucose-containing E5564 analogs and their LPS-antagonistic activities)
RN 859508-28-4 HCAPLUS
CN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
TI preparation of levulose glucoselipid A derivatives as TNFα production inhibitors
GI



I

AB Title compds. I [Q = O, etc.; W = O, NH; R1 = (un)substituted alkanoyl, etc. with the proviso that if W = NH; R1 (with the proviso that if W = O), R2, R3, R4 = H, (un)sunstituted alkyl, etc.; R5 = H, halo, etc.] were prepared For example, phosphorylation of 4-O-(allyloxycarbonyl)-3-O-decyl-2-deoxy-6-O-[4-O-diallylphosphono-3-O-[(R)-3-methoxydecyl]-6-O-methyl-2-O-[(Z)-11-octadecenoyl]-β-D-glucopyranosyl]-2-(3-oxotetradecanoylamino)-α-D-glucopyranoside, e.g., prepared from 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose in 15 steps, with diallyl diisopropylphosphoramidate followed by deallylation using Pd(PPh3)4 afforded phosphono 3-O-decyl-2-deoxy-6-O-[3-O-[(R)-3-methoxydecyl]-6-O-methyl-2-O-[(Z)-11-octadecenoyl]-4-O-phosphono-β-D-glucopyranosyl]-2-(3-oxotetradecanoylamino)-α-D-glucopyranoside (II). In TNFα production inhibition assays, the IC50 value of compound II was 0.49 nM. Compds. I are claimed useful for the treatment of inflammation, septicemia, etc.
AN 2005:638895 HCAPLUS <<LOGINID::20101022>>
DN 143:153644
TI preparation of levulose glucoselipid A derivatives as TNFα

production inhibitors
IN Shiozaki, Masao; Shimozato, Takaichi
PA Sankyo Company, Limited, Japan
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005066193	A1	20050721	WO 2005-JP434	20050107
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2552218	A1	20050721	CA 2005-2552218	20050107
	CA 2552218	C	20100622		
	JP 2005220130	A	20050818	JP 2005-2028	20050107
	EP 1702926	A1	20060920	EP 2005-703673	20050107
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1930180	A	20070314	CN 2005-80007429	20050107
	BR 2005006671	A	20070515	BR 2005-6671	20050107
	IN 2006KN01892	A	20070511	IN 2006-KN1892	20060706
	MX 2006007822	A	20060926	MX 2006-7822	20060707
	KR 2006121293	A	20061128	KR 2006-7013689	20060707
	US 20090062214	A1	20090305	US 2008-585640	20080929
PRAI	JP 2004-2902	A	20040108		
	WO 2005-JP434	W	20050107		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 143:153644
IT 859508-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of levulose glucoselipid A derivs. as TNFα production inhibitors for treatment of inflammation, septicemia, etc.)
RN 859508-28-4 HCAPLUS
CN β-D-Glucopyranoside, (1E)-1-propen-1-yl 3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides methods for preparing lipopolysaccharides (LPS) antagonist lipo-disaccharide B1287 and stereoisomers thereof, which compds. are useful as in the prophylactic and affirmative treatment of endotoxemia including sepsis, septicemia and various forms of septic shock (no biol. data). Also provided are synthetic intermediates useful for implementing the inventive methods. Thus, lipo-disaccharide B1287 I was prepared for treatment of various forms of septic shock.
AN 2004:718552 HCAPLUS <<LOGINID::20101022>>
DN 141:225771
TI Reagents and methods for preparing lipopolysaccharides antagonist B1287 and stereoisomers thereof for treatment of various forms of septic shock
IN Fan, Rulin
PA Eisai Co, Ltd., Japan
SO PCT Int. Appl., 175 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074303	A2	20040902	WO 2004-US4921	20040218
	WO 2004074303	A3	20041229		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2006518394	T	20060810	JP 2006-503710	20040218
	US 20060160999	A1	20060720	US 2005-546132	20051212
PRAI	US 2003-448839P	P	20030220		
	WO 2004-US4921	W	20040218		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 141:225771; MARPAT 141:225771
IT 748165-24-4P 748165-25-5P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reagents and methods for preparing lipopolysaccharides antagonist b and stereoisomers thereof for treatment of various forms of septic shock)
RN 748165-24-4 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl
3-O-decyl-2-deoxy-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 748165-25-5 HCAPLUS
CN α-D-Glucopyranoside, (1Z)-1-propen-1-yl
3-O-decyl-2-deoxy-6-O-[(1,1-dimethylethyl)dimethylsilyl]-2-[(1,3-dioxotetradecyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT